Prasad S. Adusumilli, MD, FACS
Deputy Chief and Attending, Thoracic Service; Vice Chair for Translational Research, Department of Surgery; Co-Director, Mesothelioma Program; Head, Solid Tumors Cell Therapy, Cellular Therapeutics Center
Lung Cancer; Mesothelioma; Metastatic Cancers to the Lung; Mediastinal and Chest Wall Tumors; Thymoma; Pleurectomy; Video-assisted thoracic Surgery (VATS); Lobectomy; Robotic Bronchoscopy; Esophageal Cancer; Laparoscopy
We post reviews for MSK healthcare providers who have at least 30 patient experience surveys completed. If you do not see reviews for a provider, it may be because they do not yet have enough survey responses, or the provider may not be part of the group of healthcare providers included in the survey.
Only outpatient providers are included in the survey. Healthcare providers who only work in the hospital or in urgent care are not included in the survey. Pathologists or researchers who do not provide direct care to patients do not have reviews.
New Patient Appointments
Scheduling a visit is easy. Click below or call us to get started.
Dr. Adusumilli accepts the following list of insurance providers. Select your insurance provider to see more details.
Memorial Sloan Kettering is an in-network provider with Aetna HMO, POS, and PPO plans. Aetna does not include us in any of the plans you can purchase through the insurance exchanges or through Medicare. Please ask your insurance if you need a one-time referral. MSK has an agreement with the Aetna Transplant Program for all Aetna's commercial products.
Memorial Sloan Kettering is a designated Blue Distinction Center for bone marrow transplant and CAR-T.
We understand that there may be many complexities involved with insurance coverage purchased through the health exchange network of the Affordable Care Act. We’re here to help. If you have questions about how your care will be covered by an insurance provider, or need help navigating a change in coverage, please call us at 646-227-3378; if you are not a resident of New York, you can call us at 866-248-1274. Our team is here to listen to your concerns and assist you in any way we can. We want our care to be as accessible and affordable for as many people as possible.
Memorial Sloan Kettering is an in-network provider with CIGNA's HMO, POS, and PPO plans. CIGNA does not include us in any of the plans you can buy through the insurance exchanges.
- If you are a New York State resident: Please ask your insurance if you need a one-time referral.
- If you live outside of New York State: Please ask your insurance if you have in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with EmblemHealth’s PPO, EPO, POS, HMO plans. EmblemHealth includes GHI, HIP, Vytra, and ConnecticCare (in NYS Only). You must bring a referral from your Emblem primary care doctor to your first appointment. In-network participation exceptions include:
- Emblem’s HIP Commercial Millennium, Select Care and Enhanced Care Prime networks is not in-network with Memorial Sloan Kettering.
- Please call Emblem to confirm if your specific plan is in-network.
For information regarding Memorial Sloan Kettering’s participation with Emblem’s Medicare Advantage Plans, please refer to the Medicare & Medicaid page
Memorial Sloan Kettering is an in-network provider with Empire Blue Cross Blue Shield (Wellpoint) of New York Indemnity, HMO, EPO, PPO, POS and Medicare Advantage plans, with the following exceptions:
- Empire Blue Cross Blue Shield does not include us in any of the plans you can buy through the insurance exchanges.
- Please call Empire BCBS to confirm if your specific plan is in-network with Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with HealthFirst’s commercial products; these commercial products are not purchased on the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with HealthSmart’s Accel, HSPC, and HPO networks.
For our NJ locations, Memorial Sloan Kettering is an in-network provider with most Horizon Blue Cross Blue Shield of New Jersey plans for individuals, families, and small businesses. Horizon members with Blue Card Access (there would be a suitcase logo on the front of the card) may have access to our NY locations. Please call Horizon to confirm if your plan is in-network in NY.
Memorial Sloan Kettering is a designated Center of Excellence by Humana.
Memorial Sloan Kettering is a designated Center of Excellence by Interlink Health Services.
Memorial Sloan Kettering is a designated Center of Excellence by Lifetrac.
Memorial Sloan Kettering is an in-network provider for all MagnaCare health plans except those products you can buy through the insurance exchanges.
For information about Medicare and Medicaid, please visit this page
Memorial Sloan Kettering is an in-network provider with some Multiplan/Beech Street/PHCS plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is a designated Center of Excellence by Multiplan.
If you are covered by more than one insurance plan, you will want to determine your benefits from both plans. First, you need to determine which one is your primary insurance provider by contacting your employee benefits office or your insurance carriers. After you find out which is your primary insurance provider, you should then contact your insurance carrier to determine if you have access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with some MVP plans. Contact your insurance carrier to find out if your plan provides in-network access to Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider for New York State employees who have enrolled in UnitedHealthcare's Cancer Resource Services. If you have the Empire Plan, you should call Cancer Resources Services at 866-936-6002 to verify and enroll in this coverage.
Memorial Sloan Kettering is in-network with Oscar’s Circle Plus Network, a part of its Small Group Broad line that is offered only to select small business groups. Oscar does not include Memorial Sloan Kettering as an in-network provider for any of its individual plans. Please confirm eligibility with your insurance carrier.
Most Blue Cross Blue Shield plans include Memorial Sloan Kettering as an in-network provider. Contact your insurance company to confirm if Memorial Sloan Kettering is in-network.
We have agreements with several insurance companies that may provide additional coverage for cancer patients. These benefit programs include:
- AXA Assistance USA
- Beech Street
- Integrated Health Plans
- National Health Administrators
- National Preferred Provider Network
- UnitedHealthcare's Cancer Resource Services
- United Resource Network
- Veterans Choice Program
Memorial Sloan Kettering is an in-network provider with Oxford’s Freedom and Liberty plans as well as the Metro Plan (which is only offered to small business groups and no longer offered as individual plans). Please confirm with your insurance if you need a one-time referral. Note: Oxford’s Medicare Managed Care plan — Secure Horizon — does not include Memorial Sloan Kettering as an in-network provider. Oxford does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is an in-network provider with the World Trade Center Health Program.
Memorial Sloan Kettering is an in-network provider with QualCare's PPO and HMO/POS network.
Memorial Sloan Kettering is a designated Center of Excellence by Specialty Care Management.
Hospital and physician services may be covered by TRICARE. Please call your TRICARE plan to confirm coverage at Memorial Sloan Kettering.
Memorial Sloan Kettering is an in-network provider with UnitedHealthCare's HMO, POS, and PPO plans. Please confirm with your insurance if a one-time referral is needed.
UnitedHealthCare's Medicare Managed Care plan does not include Memorial Sloan Kettering as an in-network provider.
United does not include us in any of the plans you can buy through the insurance exchanges.
Memorial Sloan Kettering is a designated Center of Excellence by UnitedHealthcare.
Contact and Location
Memorial Sloan Kettering has locations throughout New York City, Long Island, New Jersey, and Westchester. These locations offer many services, including screening, chemotherapy, and medical testing.
MD, Guntur Medical College, India
Surgery - Southampton University Hospitals, UK; General Surgery - Maimonides Medical Center; General Surgery - Lenox Hill Hospital
Cardiothoracic Surgery - Maimonides Medical Center; Thoracic Surgery - Memorial Sloan Kettering Cancer Center; Cardiothoracic Surgery - University of Pittsburgh Medical Center
Thoracic Surgery; General Surgery
I am a thoracic surgeon with expertise in the diagnosis and treatment of cancers of the chest — lung cancer, mesothelioma, thymoma, mediastinal and chest wall tumors, esophageal cancer, and cancers that have spread to the lung and pleura (layers of protective tissue that surround the lungs).
I see approximately 600 patients annually and have been caring for people with thoracic cancers for the past 15 years. I have expertise in the diagnostic workup needed for the early diagnosis and accurate staging of thoracic cancers, using endoscopic methods such as endobronchial ultrasound (EBUS), robotic bronchoscopy, and video-assisted thoracoscopic surgery (VATS).
When newly diagnosed patients and their family members first meet me in the clinic, they are anxious and can be overwhelmed by finding a treatment that will give them the best results and prevent the cancer from coming back. I take the time to explain the key factors that are driving the disease, possible treatment options, the risks and benefits, and the expected short-term and long-term outcomes.
Understanding their anxiety, I meet with patients again to answer their questions before finalizing their care plan. I want them to feel reassured that every possible therapy is being considered and that we are also focused on their quality of life. Not only should they feel confident in their care but they should also be assured they will be treated as a whole person — someone with a family, a job, and a desire not to be defined by their cancer diagnosis.
I work closely with thoracic pathologists, interventional radiologists, and pulmonologists to build a personalized treatment plan for each patient. My highly experienced clinical team, which includes a thoracic nurse and a nurse practitioner, works with me to deliver not only excellent care but also to provide personal attention to the needs of our patients and their family members using all available MSK resources.
As a surgeon-scientist, I have the unique perspective of treating patients in person and studying cancer in the lab. My research focuses on the development of biomarkers for detection of high-risk cancer and gene therapies, such as immunotherapy (enhancing patients’ own immune systems using genetic and cell engineering) and oncolytic viral therapy (killing cancer cells using genetically engineered viruses). I am working with my colleagues in medical and radiation oncology to integrate these therapies to help improve outcomes and preserve quality of life.
My laboratory has led many discoveries about early-stage lung cancer and mesothelioma, and we have successfully translated these findings to benefit patients. At their annual follow-up appointments after surgery, I make sure my patients are aware of these and other important developments that may help them.
Our immunotherapy research has been translated into clinical trials for patients with mesothelioma, lung cancer, and esophageal cancer (protocols 15-007, 16-040 and 20-328). This work is supported by the National Cancer Institute, the Department of Defense, the American Association for Cancer Research, the International Association for the Study of Lung Cancer, and several other foundations.
I am also privileged to mentor surgical trainees and research fellows. The high caliber of their training is reflected in their presentations at national and international conferences and submissions to peer-reviewed publications.
In my spare time, I love to write and have published several satirical science fiction articles. I also enjoy cooking for my family and children and traveling internationally, especially visiting friends in rural areas of Europe.
- Clinical Trials Co-Investigated by Dr. Adusumilli
- A Phase I/II Study of TC-210 Gene Therapy in People with Advanced Mesothelin-Expressing Cancers
- A Study of Nivolumab Immunotherapy and Chemotherapy followed by Surgery for Pleural Mesothelioma
Memorial Sloan Kettering's doctors and scientists are constantly developing new treatments for cancer. MSK is typically running hundreds of clinical trials at a given time.
You may be able to participate in a clinical trial even if you are new to MSK. Search our online directory to find trial information and see more about who can participate.
Research and Publications
Adusumilli PS, Zauderer M, Riviere I, …Jones DR, Sadelain M. A phase I trial of regional mesothelin-targeted CAR T-cell therapy in patients with malignant pleural disease, in combination with the anti-PD1 agent pembrolizumab. Cancer Discovery 2021.
Cherkassky L, Morello A, Villena-Vargas J, Feng Y, Dimitrov DS, Jones DR, Sadelain M, Adusumilli PS. Human CAR T cells with cell-intrinsic PD-1 checkpoint blockade resist tumor-mediated inhibition. J Clin Invest. 2016;126(8):3130-44.
Kadota K, Nitadori JI, Sima CS, Ujiie H, Rizk NP, Jones DR, Adusumilli PS, Travis WD. Tumor Spread through Air Spaces is an Important Pattern of Invasion and Impacts the Frequency and Location of Recurrences after Limited Resection for Small Stage I Lung Adenocarcinomas. J Thorac Oncol. 2015; 10(5):806-814.
Adusumilli PS, Cherkassky L, Villena-Vargas J, Colovos C, Servais E, Plotkin J, Jones DR, Sadelain M. Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity. Sci Transl Med. 2014;6(261):261ra151.
Nitadori J, Bograd AJ, Kadota K, Sima CS, Rizk NP, Morales EA, Rusch VW, Travis WD, Adusumilli PS. Impact of micropapillary histologic subtype in selecting limited resection vs lobectomy for lung adenocarcinoma of 2 cm or smaller. J Natl Cancer Inst. 2013;105(16):1212-20.
Suzuki K, Kadota K, Sima CS, Nitadori J, Rusch VW, Travis W, Sadelain M, Adusumilli PS. Clinical impact of immune microenvironment in stage I lung adenocarcinoma: tumor IL-12R & IL-7R, and stromal FoxP3/CD3 ratio are independent predictors of recurrence. J Clin Oncol. 2013;31(4):490-98.
At MSK, we’re committed to delivering the best care to every patient. We use feedback from our patients to continue to improve our care. We also post patient reviews online to help you make healthcare choices. Learn more about our patient experience reviews.
Doctors and faculty members often work with pharmaceutical, device, biotechnology, and life sciences companies, and other organizations outside of MSK, to find safe and effective cancer treatments, to improve patient care, and to educate the health care community.
MSK requires doctors and faculty members to report (“disclose”) the relationships and financial interests they have with external entities. As a commitment to transparency with our community, we make that information available to the public.
Prasad S. Adusumilli discloses the following relationships and financial interests:
Provision of Services
Johnson & Johnson
Provision of Services
MJH Life Sciences
Provision of Services
Provision of Services
Provision of Services
Society for Immunotherapy of Cancer
Provision of Services
Provision of Services
University of Pittsburgh
Provision of Services
If you’re a patient at MSK and would like more information about your doctor’s external relationships, please talk with your doctor.
The information published here is for a specific annual disclosure period. There may be differences between information on this and other public sites as a result of different reporting periods and/or the various ways relationships and financial interests are categorized by organizations that publish such data.
This page and data include information for a specific MSK annual disclosure period (January 1, 2021 through disclosure submission in spring 2022). This data reflects interests that may or may not still exist. This data is updated annually.